Two more for AtCor
Monday, 08 December, 2008
Medical device company AtCor has signed two new supply agreements worth US$1.5 million for its reflected blood pressure measurement system SphygmoCor.
The new agreements cap an excellent six months for the Sydney company, with supply contracts signed in the period worth US$5.7 million.
The device is aimed at both clinical practice and clinical trials to understand drug efficacy and mechanisms of action.
The SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring.
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
